Non-Small Cell Lung Cancer

Risk and Outcomes of Secondary Cancer Among Lung Cancer Survivors After Definitive Treatment: A Comprehensive Review

By MedXY 12/13/2025

This review synthesizes evidence on the incidence, risk factors, and outcomes of secondary cancers in non-small cell lung cancer survivors post-definitive therapy, highlighting genetic predisposition as a key determinant distinct from recurrence patterns.

Clinical Updates news Oncology

Encorafenib Plus Binimetinib in BRAF V600E-Mutant Metastatic NSCLC: Insights from the Phase II PHAROS Study and Updated Survival Outcomes

By MedXY 12/09/2025

The Phase II PHAROS study demonstrates durable antitumor efficacy and manageable safety of encorafenib plus binimetinib in BRAF V600E-mutant metastatic NSCLC, with updated results showing the longest median overall survival reported for targeted therapy in this setting.

news Oncology

Amivantamab Plus Lazertinib Shows Promising Activity in Atypical EGFR-Mutant Advanced NSCLC: CHRYSALIS‑2 Cohort C Results

By MedXY 12/08/2025

In CHRYSALIS‑2 Cohort C, the amivantamab plus lazertinib combination produced a 52% ORR and durable responses (mDoR 14.1 months) in advanced NSCLC with atypical EGFR mutations, with higher activity in treatment‑naïve patients and an expected safety profile.

news Oncology Respiratory

Retifanlimab Plus Chemotherapy Significantly Prolongs Survival in Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial

By MedXY 10/15/2025

The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeutic option with manageable safety.

news Oncology Respiratory

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression

By MedXY 10/15/2025

The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety profile, suggesting a viable alternative treatment approach.

Anesthesiology General Surgery Oncology Specialties

Optimizing Anesthesia in Elderly NSCLC Patients: Impact of Midazolam and Dexmedetomidine Co-Administration on Hemodynamics and Stress Response

By MedXY 09/15/2025

Co-administering midazolam with dexmedetomidine in elderly NSCLC patients undergoing lobectomy enhances hemodynamic stability and reduces perioperative stress response, potentially improving recovery outcomes without increasing adverse events.

Clinical Updates Oncology Specialties

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy

By MedXY 09/08/2025

Patritumab deruxtecan (HER3-DXd) demonstrates notable efficacy and manageable safety in heavily pretreated advanced NSCLC, including patients without EGFR mutations, offering a potential new treatment avenue.

news Oncology Specialties

Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial

By MedXY 08/15/2025

The KRYSTAL-12 trial demonstrated that adagrasib significantly improves progression-free survival compared to docetaxel in previously treated KRASG12C-mutated advanced NSCLC, with manageable safety profiles.